National Institute for Health and Care Excellence

October 23, 2017October 23, 2017

Opdivo Not Recommended for Treating Urothelial Carcinoma in the UK

News

The U.K.’s National Institute for Health and Care Excellence (NICE) does not recommend Opdivo (nivolumab) treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC) after platinum-containing chemotherapy. NICE provides national guidance ... Read more

April 21, 2017

Opdivo for Head-Neck Cancers Too Costly for UK Patients, NICE Rules

News

Opdivo (nivolumab) likely will not be available for United Kingdom patients with head and neck cancers, because the U.K. cost-benefit agency, the National Institute for Health and Care Excellence (NICE), ... Read more

October 27, 2016October 27, 2016

In Reversal, NICE Agrees to Add Opdivo to NHS Treatments for Advanced Kidney Cancer Patients

News

The National Institute for Health and Care Excellence (NICE) has reversed its draft decision, and is now recommending that Opdivo (nivolumab) be available to National Health Service (NHS) patients with renal ... Read more

June 21, 2016June 21, 2016

NHS Approves Immunotherapy Combination for Metastatic Melanoma

News

Metastatic melanoma patients in England and Wales will be the first in Europe to benefit from the combined immunotherapy regimen of nivolumab (Opdivo) and ipilimumab (Yervoy). The therapy was recently approved by the National Institute for Health and Care Excellence (NICE). When ... Read more